CJC-1295 NO DAC + Ipamorelin (10mg)
A blend of CJC-1295 (no DAC) (5 mg), a modified GHRH(1-29) analog, and Ipamorelin (5 mg), a selective pentapeptide ghrelin mimetic. Unlike the version with DAC, CJC-1295 (no DAC) produces shorter but more physiological GH pulses, while Ipamorelin selectively stimulates GH without increasing ACTH or cortisol. Administered subcutaneously once daily.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
CJC-1295 (no DAC) is a modified GHRH(1-29) analog without a Drug Affinity Complex, resulting in a shorter half-life (~30 minutes) but more physiological GH pulse rhythms. It produces dose-dependent increases in GH/IGF-1 without the prolonged elevation of the DAC version. Ipamorelin is a selective pentapeptide ghrelin mimetic that binds to the GHS-R1a receptor, stimulating rapid GH release (~25 minutes) without increasing ACTH, cortisol, or prolactin. The combination produces **synergistic GH pulses** — GHRH signaling 'primes' the somatotroph cell, while GHS signaling 'amplifies' the release.
Quick Start
- Reconstitution: Add 3.0 mL of bacteriostatic water → ~3.33 mg/mL (1.67 mg/mL per peptide).
- Typical daily range: 100–300 mcg per peptide (200–600 mcg total) with gradual titration.
- Storage: Lyophilized: freeze at −20 °C · after reconstitution: refrigerate at 2–8 °C · use within 2–4 weeks.
Gradual Titration (3 mL = ~3.33 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 100 mcg/peptide (200 mcg total) | 3 Units (0.03 mL) |
| Weeks 3–4 | 150 mcg/peptide (300 mcg total) | 4.5 Units (0.04 mL) |
| Weeks 5–6 | 200 mcg/peptide (400 mcg total) | 6 Units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg/peptide (500–600 mcg total) | 7.5–9 Units (0.07–0.09 mL) |
Studies report administration once daily subcutaneously, preferably at bedtime or in the morning depending on goals. 30–50 unit syringes offer better precision for these small volumes.
Reconstitution Steps
- Draw up 3.0 mL of bacteriostatic water with a sterile syringe.
- Inject slowly against the vial wall · avoid foaming.
- Gently swirl or rotate until fully dissolved (do not shake vigorously).
- Note reconstitution date and concentration (~3.33 mg/mL) · refrigerate at 2–8 °C, protecting from light.
Protocol Overview
- Goal: Pulsatile GH release via synergistic GHRH + GHS action — more physiological rhythm compared to the DAC version.
- Schedule: Daily subcutaneous injections for 8–12 weeks, followed by a 4-week washout period.
- Storage: Lyophilized frozen · reconstituted refrigerated · use within 2–4 weeks.
Dosing Protocol
- Start: 100 mcg per peptide daily (3 units) to assess tolerance.
- Increase: +50 mcg every 2 weeks: 150 mcg (Wks 3–4) → 200 mcg (Wks 5–6).
- Target: 200–300 mcg per peptide (6–9 units) in weeks 7–12.
- Cycle Duration: 8–12 weeks on, 4 weeks off.
- Break between cycles: After the cycle, a 4–6 week washout period is recommended. The pause prevents tolerance to GHRH/GHSR receptors and restores endogenous GH.
Washout & Cycle Restart
When can I restart?
After the cycle, a 4–6 week washout period is recommended. The pause prevents tolerance to GHRH/GHSR receptors and restores endogenous GH.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C for long-term · 2–8 °C for short-term.
- Reconstituted: 2–8 °C · use within 2–4 weeks · avoid freeze-thaw cycles.
- Allow frozen vials to reach room temperature before opening.
Important Notes
- Aseptic technique: clean the vial stopper and skin with separate alcohol pads.
- The no-DAC version provides more physiological GH pulses vs DAC — ideal for beginners.
Potential Benefits & Side Effects
Potential Benefits:
- Selective increase in GH without elevating cortisol, ACTH, or prolactin.
- Synergistic GH pulses significantly stronger than single-agent use.
- More physiological GH rhythm compared to the DAC version — ideal for beginners.
- Improved body composition, sleep quality, and recovery.
- Good tolerability profile in clinical studies.
Potential Side Effects:
- Mild injection site reaction (redness, itching).
- Rare transient dizziness or tingling.
- Generally very well-tolerated — fewer side effects than GHRP-2/GHRP-6.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical risk (GH/IGF-1 elevation)
As a GHS, increases GH. Theoretical risk for pre-existing neoplasms due to IGF-1 elevation. No clinical signal in short-term studies.
📄 Growth Horm IGF Res 2008References
- J Clin Endocrinol Metab — CJC-1295: pharmacokinetics and dose-dependent GH increase
View Source - Growth Hormone & IGF Research — Ipamorelin: selective GH release without ACTH/cortisol
View Source - Eur J Endocrinol — Ipamorelin: the first selective GH secretagogue
View Source - Endocrine Reviews — GH secretagogues: mechanisms & clinical applications
View Source
External Sources & Regulatory Status
Regulatory Approvals
Postoperative ileus
Phase II (development discontinued)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →